BioNTech: The Founders Go, the Cash Stays — About 65 Euros per Share

The founder bonus: why you buy faces instead of balance sheets

There is a weakness that looks smarter than it is: we buy people. A company with a founder whose story we know feels safer than one run by an interchangeable board. At BioNTech SE (Nasdaq: BNTX) that founder bonus was unusually large for years: Ugur Sahin and Özlem Türeci, the research couple from Mainz who delivered the first approved mRNA vaccine against COVID-19 in the winter of 2020. Buying the stock meant buying a promise with two faces attached.

On August 3, 2026 the Supervisory Board rewrote that promise. It appointed Guido Oelkers as the new Chief Executive Officer — taking office by February 1, 2027, at the latest — and Özlem Türeci is leaving the Management Board to lead a new, independent company with Sahin. One day later, on August 4, 2026, BioNTech cut its own revenue guidance for 2026. On November 3, 2026 the third-quarter numbers followed: a profit that would not have existed without license money, and a cash pile that shrank anyway.

So we are going to do something unromantic here: set the faces aside and read the mandatory filings to the U.S. securities regulator, the SEC. And because BioNTech is treated there as a foreign private issuer, those filings carry different names than at U.S. companies — more on that shortly. The central tension of this analysis is already clear: the cash pile is enormous and real, the operating business keeps shrinking — and the people investors trusted are clearing the bridge.

What BioNTech actually is

BioNTech was founded in Mainz in 2008 and listed on Nasdaq on October 10, 2019. As of December 31, 2025 it employed 7,807 full-time equivalents, of whom 1,310 hold a doctoral degree or higher. The business rests on four legs, and only one of them makes meaningful money from products it sells.

First, the COVID-19 vaccine. BioNTech develops and markets it together with Pfizer. This matters for reading the numbers: across much of the world BioNTech does not sell the vaccine itself but receives a share of its partner's gross profit. What appears as revenue in the income statement is therefore largely a profit share — and it falls faster than unit sales because it sits at the end of the chain. In 2025 this business brought in 1,995.3 million euros, down from 2,432.1 million in 2024, a decline of 18 percent. For the 2026–2027 season the XFG variant-adapted vaccine is approved: by the European Commission in July 2026 and by the U.S. Food and Drug Administration in August 2026, there for adults 65 and older and for people aged 5 through 64 with at least one underlying condition that puts them at high risk of severe COVID-19 (FDA: Form 6-K filed August 27, 2026; EU and FDA approvals together: third-quarter 2026 earnings release, Exhibit 99.1 to the Form 6-K of November 3, 2026).

Second, oncology — the declared future. According to the second-quarter 2026 earnings release of August 4, 2026, 14 pivotal trials were ongoing at that point. The most important candidate is pumitamig (development name BNT327), a bispecific antibody. Picture a bouncer with two hands: one blocks the tumor's cloak against the immune system (PD-L1), the other cuts off its blood supply (VEGF-A). As of September 30, 2026, BioNTech and Bristol Myers Squibb have seven global registrational trials for pumitamig ongoing. Alongside it sit gotistobart (BNT316, with OncoC4) and two antibody-drug conjugates developed with the Chinese partner DualityBio: trastuzumab pamirtecan (BNT323) and elfetabart drozuntecan (BNT324). Antibody-drug conjugate sounds technical but the image is simple: an antibody acts as a courier that delivers a chemotherapy payload directly to the tumor cell instead of spreading it through the whole body.

Third, acquisitions. In July 2023 BioNTech bought the AI company InstaDeep, in January 2025 the Chinese antibody developer Biotheus, and in December 2025 the Tübingen mRNA pioneer CureVac for total consideration of about 400 million euros. The InstaDeep purchase was meant to be more than a tool acquisition: the annual report for 2025 treats InstaDeep's external business as its own valuation unit and explicitly counts BioNTech among the competitors in the AI industry.

“Following our acquisition of InstaDeep Ltd., or InstaDeep, we also face competition in the rapidly growing and developing artificial intelligence, or AI, industry.”

— BioNTech SE, annual report on Form 20-F for 2025, Item 3.D Risk Factors

With the interim report for the period ended September 30, 2026, BioNTech changes direction. The AI business that also worked for third parties is to become an internal tool:

“For InstaDeep, we plan to integrate its expertise and capabilities directly into BioNTech’s core business. Moving forward, AI development at BioNTech will focus on supporting BioNTech’s strategic goals, operational processes, and innovation priorities. We believe that sharpening our focus reduces complexity and enables us to leverage AI more effectively where it matters most.”

— BioNTech SE, interim report on Form 6-K for the period ended September 30, 2026, section “InstaDeep Integration”

According to the same report, BioNTech will build its own AI only where it has highly specific needs, such as neoantigen detection; otherwise it will turn to ready-made solutions from the market. The same report also records a 96.0 million euro impairment on a technology asset in the third quarter of 2026, attributed to “a shift towards next-generation AI models and technologies.” The report does not say which unit that asset belongs to.

Fourth, the cash. What survived the pandemic years is by far the largest item on the balance sheet. We get to that in the valuation section.

A word on the filings: Form 20-F, not Form 10-K

BioNTech is a German-domiciled European company (SE) headquartered in Mainz whose shares trade on Nasdaq. The SEC classifies such companies as foreign private issuers. In practice that means: instead of a U.S. annual report (Form 10-K) there is an annual report on Form 20-F, and instead of quarterly reports (Form 10-Q) there are interim reports on Form 6-K. BioNTech files no Form 10-Q at all. It reports under IFRS and in euros while the stock trades in U.S. dollars. That currency gap is not a footnote: it is the reason some automatically calculated ratios simply make no sense here, because a euro balance sheet cannot be held against a dollar market value without conversion. We therefore keep this analysis in euros, exactly as the company does.

How the stock reached our desk

Not through a momentum filter but through the calendar: within 48 hours in August 2026, BioNTech announced a leadership change and cut its guidance. That combination is the classic moment when a stock gets repriced — and the moment when reading the filings beats reading the headlines. With the third-quarter interim report filed on November 3, 2026, we updated this analysis on November 8, 2026.

In our in-house stock scanner BioNTech is a special case worth understanding. Because the balance sheet is in euros while the listing is in U.S. dollars, several absolute metrics — Altman Z-score, net current asset value per share, cash per share — are deliberately left blank. A number here would not be a better number, it would be a wrong one. Remember the principle: an empty cell is more honest than a false figure. What the scanner did show was the valuation relationship: as of August 12, 2026 the market value stood at roughly 23.3 billion U.S. dollars and the price-to-book ratio at about 1.1 — the market was paying roughly what the balance sheet says, and little more.

For a thematically related calculation: we ran the same post-pandemic transition through the numbers at Moderna — there with a far smaller cash pile and a loan secured against the company's assets. The comparison is worth the time, because the same technology left behind two very different balance sheets.

The numbers over the years — given their due

Start with what genuinely impresses: BioNTech reported a combined profit of about 19.7 billion euros for 2021 and 2022. In 2021 the books showed 18,976.7 million euros of revenue and 10,292.5 million euros of profit; in 2022 it was 17,310.6 million and 9,434.4 million. Diluted earnings per share reached 39.63 euros in 2021. That was not a bubble — it was billed, delivered business.

Then came the fall. In 2023 revenue dropped to 3,819.0 million euros and profit to 930.3 million. In 2024 the company slipped to a loss of 665.3 million on revenue of 2,751.1 million. In 2025 revenue edged up to 2,869.9 million — but only because an out-licensing deal contributed 613.0 million euros that did not exist in 2024; the vaccine business itself kept shrinking. The loss widened to 1,136.1 million euros.

The first half of 2026 continued the trend. In the second quarter of 2026 revenue came to 105.6 million euros against 260.8 million in the prior-year quarter — a decline of about 60 percent. The quarterly loss doubled to 820.8 million euros. Across the first half of 2026 revenue was 223.7 million euros against a loss of 1,352.7 million, with diluted loss per share of 5.34 euros.

Where the loss comes from is no mystery: research and development cost 1,108.0 million euros in the first half of 2026 — five times the revenue over the same period. Add 348.6 million euros of selling, general and administrative expenses for a commercial build-up that is not yet selling anything. That is the arithmetic of a company constructing a new business before the old one runs out.

One detail that is easy to miss: operating cash flow in 2025 was positive at 456.0 million euros — despite the 1,136.1 million loss. The reason was the 1.5 billion U.S. dollar upfront payment from Bristol Myers Squibb. In the first half of 2026 operating cash flow flipped to negative 410.5 million euros, and after nine months it stood at negative 540.3 million. Remember: a positive cash flow that comes from a one-time payment is no proof of a sustainable business.

The third quarter of 2026: profit from license fees, cash out the door

On November 3, 2026 BioNTech reported its numbers for July through September 2026. At first glance it is the best quarter of the year: 1,289.2 million euros of revenue and net income of 184.5 million euros, after a loss of 28.7 million in the prior-year quarter. Diluted earnings per share came to 0.73 euros. Compared with the third quarter of 2025 (1,518.9 million euros), however, revenue fell by about 15 percent.

What matters is what that revenue is made of. The COVID-19 vaccine brought in 554.3 million euros, down from 853.3 million in the prior-year quarter — a decline of 35 percent. Out-licensing revenue came to 683.0 million euros: 613.0 million from the Bristol Myers Squibb pumitamig agreement and 70.0 million from a development milestone on an out-licensed research program. Other revenue was 51.9 million euros (prior-year quarter: 52.6 million). Do the math: 683.0 of 1,289.2 million is about 53 percent. More than half of the quarter's revenue is contract revenue, not a product sale. And out-licensing revenue exceeds the entire profit: profit before tax was 222.0 million euros, net income 184.5 million. A simplified calculation of our own that ignores possible cost effects (under the 50:50 cost sharing with Bristol Myers Squibb, part of the research costs is tied to this agreement): 222.0 minus 683.0 million gives a pre-tax result of about negative 461 million euros. The quarter was profitable only because of out-licensing revenue.

The profit has a second catch: it is not cash yet. Operating cash flow in the third quarter of 2026 was negative 129.8 million euros, against positive 780.7 million in the prior-year quarter. Receivables and similar items (in the cash flow statement: trade and other receivables, contract assets and other assets) rose by 489.1 million euros during the quarter. In everyday terms: the invoices have been written, but the money is not in the account yet. Cash and securities fell from about 16.6 billion euros (June 30, 2026) to about 16.2 billion euros as of September 30, 2026, a decline of 470.4 million, of which 274.3 million euros went into buying back the company's own shares — more than half.

The clean-up continued as well. In the third quarter of 2026 BioNTech recorded 191.7 million euros of impairments on intangible assets — including 67.5 million on an early clinical-stage candidate and the 96.0 million on a technology asset mentioned above — plus 44.6 million euros on property, plant and equipment. Add 19.7 million euros of employee-related restructuring costs and 13.5 million euros from settlements. Research and development cost 748.1 million euros in the quarter, up from 564.8 million a year earlier.

And the guidance? BioNTech now expects 1.7 to 1.9 billion euros of revenue for 2026. The low end was raised; the high end stayed where it was in August. Chief Financial Officer Ramón Zapata put it this way:

“Our performance in the third quarter allowed us to narrow our full-year 2026 revenue guidance to the upper end of the previous guidance range”

— Ramón Zapata, Chief Financial Officer, third-quarter 2026 earnings release, Exhibit 99.1 to the Form 6-K filed November 3, 2026

Run the numbers yourself: after nine months, 1,512.9 million euros of revenue are on the books. Guidance therefore leaves 187 to 387 million euros for the fourth quarter. Strip out the 683.0 million of out-licensing revenue and the full year 2026 comes to 1.0 to 1.2 billion euros without contract revenue — after 1,995.3 million from the vaccine alone in 2025. BioNTech confirmed its 2026 expense guidance unchanged: adjusted research and development of 2.0 to 2.3 billion euros and adjusted selling, general and administrative expenses of 700 to 800 million euros. Chief Executive Officer Ugur Sahin names the goal of becoming a “diversified, multi-product company by 2030.”

A note on sources: the earnings call took place on November 3, 2026 at 8:00 a.m. EST. No public transcript could be found through November 8, 2026. Our assessment therefore rests on the earnings release and the interim report, not on answers from the Q&A.

What has happened in the pipeline since August

The late-stage trials the future business is waiting on have delivered mixed results since August 2026:

• Trastuzumab pamirtecan (DYNASTY-Breast02): the Phase 3 trial in HR+/HER2-low breast cancer met its primary endpoint, but according to the October 26, 2026 release with a “statistically significant, yet modest improvement” in progression-free survival. Interstitial lung disease — an inflammation of the lung tissue — occurred more often than in prior trials with the same candidate, mostly mild, severe or fatal in a small proportion of patients. BioNTech and DualityBio write themselves: “The available efficacy and safety data, as of this data cut-off date, suggest that the potential benefit to patients would be limited in the context of the HR+/HER2-low metastatic breast cancer treatment landscape.”
• BNT113 (AHEAD-MERIT): the mRNA cancer immunotherapy in head and neck cancer missed its first dual primary endpoint, progression-free survival, in October 2026. On the recommendation of the independent data monitoring committee, the trial continues toward the second endpoint, overall survival.
• Gotistobart (PRESERVE-003): in stage 1 of the Phase 3 trial in previously treated squamous non-small cell lung cancer, median overall survival was 18.5 months versus 10.0 months on chemotherapy (presented on September 14, 2026, data cut-off July 17, 2026) — nearly double. The median describes the typical case: half of the patients lived longer, the other half for a shorter time.
• Pumitamig: in October 2026 BioNTech entered a clinical trial collaboration with Gilead; the first global Phase 3 trial with Gilead's sacituzumab govitecan in triple-negative breast cancer is subject to regulatory approval.
• Roche agreement: for autogene cevumeran, the mRNA candidate developed with Roche/Genentech, BioNTech exercised an option. Instead of a 50:50 cost and profit split, Roche/Genentech will generally bear future development costs from January 1, 2027, and BioNTech will be eligible for royalties if the program succeeds.

Three further items have nothing to do with trials. In October 2026 the sale of the subsidiary JPT Peptide Technologies to a fund advised by DUBAG Group closed. The Supervisory Board proposes KPMG as auditor from fiscal year 2027, subject to election by the Annual General Meeting (Form 6-K filed September 18, 2026). And a patent lawsuit filed by Translate Bio and Sanofi against Pfizer in July 2026 was extended in October 2026 to BioNTech SE and BioNTech Manufacturing GmbH; BioNTech considers its defenses strong, and the outcome is open.

What the filings say: five uncomfortable truths

Uncomfortable truth no. 1: more than half of the strongest quarter's revenue is contract revenue

In August 2026 BioNTech announced that a large share of the year's revenue would come from a single contractual payment. The background: on June 2, 2025 BioNTech signed an agreement with Bristol Myers Squibb on its most important oncology candidate, pumitamig, which was amended and restated on August 15, 2025 — with a 1.5 billion U.S. dollar upfront payment, 2.0 billion U.S. dollars of non-contingent anniversary payments through 2028, and up to 7.6 billion U.S. dollars in potential milestones. Profits and losses are shared equally, and development costs generally are as well.

“BioNTech continues to expect the majority of 2026 revenues to be realized in the second half of the year, specifically in the third quarter, when it also expects to recognize the €613 million Bristol Myers Squibb Company (“BMS”) collaboration revenue.”

— BioNTech SE, Form 6-K filed August 4, 2026, Exhibit 99.1, second-quarter 2026 earnings release

That is exactly what happened. The 613.0 million euros are on the books in the third quarter of 2026 — just as in the third quarter of 2025. The interim report also explains why the timing falls where it does:

“The revenues in the three and nine months ended September 30, 2026, were recognized at the point in time the first option to cancel the contract lapsed and the related rights became enforceable.”

— BioNTech SE, interim report on Form 6-K for the period ended September 30, 2026, Note 3 (Revenues)

In everyday terms: the partner could have walked away, did not — and the moment that door closed, the payment became revenue. According to the annual report, BioNTech allocates the expected 3.5 billion U.S. dollars from the upfront and anniversary payments to the partner's individual options to cancel; each portion becomes revenue as soon as the respective option lapses. The 613.0 million euros are therefore a portion of the contractually committed payments through 2028, and the same amount was already recognized in the third quarter of 2025. None of this is improper; such payments are standard in pharmaceuticals and accounted for correctly. But they say nothing about whether a drug will ever be sold.

Uncomfortable truth no. 2: guidance was cut mid-year — and in November only the low end was raised

In March 2026 BioNTech still pointed to 2.0 to 2.3 billion euros of revenue for the year. On August 4, 2026 that became 1.6 to 1.9 billion euros — a cut of 400 million euros at the midpoint, or just under one fifth. Chief Financial Officer Ramón Zapata attributed it to “recently emerged external developments.” The release named three specifically: softer than anticipated global COVID-19 vaccine demand, existing vaccine inventory in Germany being used up during the 2026 season — which generates no new sales — and a milestone payment from an out-licensed research program no longer expected in 2026.

At the same time BioNTech lowered planned adjusted research and development expenses from 2.2–2.5 to 2.0–2.3 billion euros. On November 3, 2026 the company raised the low end of its revenue guidance to 1.7 billion euros; the high end of 1.9 billion was left unchanged. That is good news in small change: at 1.8 billion euros, the new midpoint is still about 350 million below the March midpoint. Guidance has not recovered; it has only become more certain.

Uncomfortable truth no. 3: Marburg is being vacated

In 2020 BioNTech bought a plant in Marburg to manufacture its vaccine at a scale of billions of doses. It was the most visible sign that a research house had become a manufacturer. In the second quarter of 2026 it turned into a write-down: 96.1 million euros of impairments on property, plant and equipment and other intangible assets, of which 87.0 million euros related to the Marburg and Idar-Oberstein sites. The recoverable amount of equipment, tools and leasehold improvements was set to zero; land and buildings remained on the books at 6.8 million euros afterward. On top came 97.6 million euros of employee-related restructuring costs in that quarter alone.

“These losses mainly related to our ongoing pipeline prioritization following our decision on our manufacturing footprint consolidation, in particular, to exit operations at several manufacturing sites.”

— BioNTech SE, interim report on Form 6-K for the period ended June 30, 2026, Note 7 (Property, plant and equipment)

The third quarter of 2026 shows the restructuring continuing. Affected sites in Germany took a further 26.4 million euros of impairments with a recoverable amount of zero, plus another 15.1 million euros on buildings and equipment now carried at 19.0 million euros. After nine months, impairments on property, plant and equipment total 140.6 million euros. The restructuring provision — money set aside for severance and closures — rose from 39.1 million euros at the end of 2025 to 142.5 million euros as of September 30, 2026.

In parallel, BioNTech wrote down 318.5 million euros of intangible assets outside its strategic focus in the first nine months of 2026. Together with property, plant and equipment, that is 459.1 million euros cleared away in nine months. This is housekeeping, not growth.

Uncomfortable truth no. 4: the inherited 450 million euro bill

The CureVac acquisition of December 2025 brought a legacy item that the purchase price of about 400 million euros does not contain. In November 2020 CureVac had signed an Advance Purchase Agreement with the European Commission for up to 405 million vaccine doses and received a 450 million euro upfront payment. When CureVac withdrew its regulatory application in October 2021, the agreement terminated automatically — and any unspent portion would have to be returned. On July 24, 2024 the European Commission informed CureVac that it had engaged Deloitte to audit CureVac's compliance with the agreement. CureVac received the draft audit report on September 17, 2025; among other things, it alleged missing documentation and inconsistencies with financial information previously provided. CureVac objected on October 17, 2025, and the European Commission subsequently issued its final audit report.

“As the successor to CureVac following the acquisition, we cannot exclude the possibility of being required to repay a portion or all of the €450 million upfront payment.”

— BioNTech SE, annual report on Form 20-F for 2025, Item 3.D Risk Factors

The interim report for the period ended September 30, 2026 brings the matter up to date: the European Commission continues to formally assess it and made further requests for documents and information in 2026. BioNTech records no provision because it does not consider an outflow sufficiently probable:

“In our opinion, this matter constitutes a contingent liability as of September 30, 2026.”

— BioNTech SE, interim report on Form 6-K for the period ended September 30, 2026, notes on legal proceedings

A contingent liability is a bill that may or may not arrive: it sits in the notes, not as a figure on the balance sheet. The report adds that, as of that date, the amount could not be estimated with sufficient reliability. For scale: 450 million euros is roughly 16 percent of total group revenue for 2025 and about 2.8 percent of the cash pile as of September 30, 2026. For a company with more than 16 billion euros of liquidity that is no existential threat — but it is money nobody budgeted for. More of these research by-products in our side-finds section.

Uncomfortable truth no. 5: who owns the company — and who is leaving it

BioNTech looks like a widely held public company. It is not. As of December 31, 2025, AT Impf GmbH — the vehicle behind ATHOS KG, the investment arm of the Strüngmann family — held 101,279,878 of the 251,325,340 shares outstanding, or 40.3 percent. Ugur Sahin reached 16.4 percent on that date: 40,132,788 shares through his Medine GmbH plus 1,114,130 shares held directly. The annual report spells out the power structure itself, and remarkably plainly:

“ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions at our Annual General Meeting, or AGM.”

— BioNTech SE, annual report on Form 20-F for 2025, Item 7.A Major Shareholders

Put in everyday terms: you buy a share of a house in which somebody else holds the keys to every door. That is not necessarily bad — a long-term anchor investor can shield a research company from quarterly pressure. But it means minority shareholders can practically never form a majority against the large shareholder at the Annual General Meeting.

And above the ownership question sits the personnel question since August 3, 2026. The Supervisory Board appointed Guido Oelkers as the new Chief Executive Officer — until now head of the Swedish pharmaceutical company Swedish Orphan Biovitrum (Sobi), where, by the company's own account, he more than quadrupled revenues over nine financial years. He takes office by February 1, 2027, at the latest. The same release contains a second departure:

“As previously announced, BioNTech's Chief Medical Officer, Prof. Özlem Türeci, M.D., will transition into the management of a new, independent company, which she will lead together with her husband and co-founder, Prof. Ugur Sahin, M.D.”

— BioNTech SE, Form 6-K filed August 3, 2026, Exhibit 99.1

So the founding couple is leaving operational leadership — and building something new together. Whether BioNTech itself contributes anything to that new company is open as of September 30, 2026. The interim report states: “Discussions regarding the new company and potential contributions from BioNTech remain ongoing.” Any such transaction, it adds, is “optional for both parties and not a necessity.”

Since March 18, 2026, directors and officers of foreign private issuers have had to report their share transactions on Form 4, the U.S. insider filing. That makes visible what Sahin did in the fall of 2026: between September 3 and October 9, 2026 he sold, in daily tranches, 858,209 shares — exactly the number he had reported as directly held in his first insider filing (Form 3 of March 25, 2026); according to the last filing of October 9, 2026, he holds no shares directly afterwards. The 2025 annual report still lists 1,114,130 directly held shares as of December 31, 2025; the filings do not explain how the difference of 255,921 shares arose by March 2026. The shares were sold at daily average prices between roughly $92 and $104; by our calculation that adds up to about $84 million. Every one of these filings carries the same remark:

“The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person on June 3, 2026.”

— Ugur Sahin, Form 4 filed September 8, 2026, with identical wording in the subsequent filings through October 9, 2026

On the sequence of events: Sahin set up the plan on June 3, 2026, two months before BioNTech announced the change of chief executive on August 3, 2026. A trading plan of this kind is set up in advance and then runs on fixed rules — a common way for insiders to sell stock without deciding on the timing of each individual sale. The scale still belongs in the picture: the shares sold equaled about 2 percent of his total holding. Through Medine GmbH, Sahin still holds 39,218,111 shares, about 15.8 percent of the 247,928,180 shares outstanding as of September 30, 2026. That is less than the 16.4 percent at the end of 2025 because of how the figures are composed: the 16.4 percent also included the 1,114,130 directly held shares, and according to the last insider filing Sahin no longer holds any shares directly; in addition, the annual report lists 40,132,788 Medine shares as of December 31, 2025, while Sahin's amended filing as of March 18, 2026 shows 39,218,111 (according to the amendment, the original Form 3 of March 25, 2026 contained an incorrect number). The difference matches exactly the decline in shares Medine holds in trust for another individual (from 1,021,398 to 106,721, according to the annual report and Sahin's amended Form 3 of April 13, 2026). According to the shareholder list in the annual report for 2025, that is the second-largest stake after the family holding. Still, the fact stands: from February 2027 at the latest, someone else is at the helm.

What the market is charging for it

This is the core of the valuation question. As of September 30, 2026 BioNTech held 16,163.8 million euros in cash and security investments: 10,200.8 million as cash and cash equivalents, 4,390.2 million as current and 1,572.8 million as non-current security investments. Equity stood at 17,711.7 million euros against total assets of 20,173.8 million and total liabilities of 2,462.1 million. Put differently: about 80 percent of the balance sheet is money or securities, and there is little debt against it.

To calculate the market value in an evergreen way, we use no daily price but one documented in a mandatory filing: in the third quarter of 2026 BioNTech repurchased 3,344,396 of its own American Depositary Shares at an average price of $93.23 — stated in the report as 81.24 euros. Multiplied by the 247,928,180 shares outstanding, that gives a market value of roughly 20,141.7 million euros.

The same calculation per share, in euros like the balance sheet: cash and securities divided by 247,928,180 shares comes to about 65.20 euros per share (as of September 30, 2026). Measured against the buyback price of 81.24 euros, roughly 80 percent of the price sits on the balance sheet as cash and securities.

Deduct the cash and the market is paying roughly 3,977.9 million euros for everything else — the pivotal trials (14 according to the earnings release of August 4, 2026, seven for pumitamig alone as of September 30, 2026), the Bristol Myers Squibb contract, the vaccine profit share, InstaDeep, CureVac, Biotheus, the plants and the workforce. That is roughly 1.7 to 2.0 years of adjusted research spending, measured against 2026 guidance.

How should you read that? There are two honest readings and both are defensible. Reading one: the market values the oncology pipeline at a fraction of the cash because it has little confidence in it. Reading two: the market assumes the cash will be burned over the coming years and therefore refuses to value it fully. With an operating cash outflow of 540.3 million euros in the first nine months of 2026 and planned adjusted research spending of 2.0 to 2.3 billion euros for the full year, that concern is not unreasonable.

How long the cash lasts depends on the basis of the calculation — here is our own: annualized, the operating cash outflow of the first nine months of 2026 comes to about 720 million euros; at that pace, 16.2 billion euros would last a good twenty years on paper. But that outflow already includes the revenue from the vaccine and out-licensing. If BioNTech had to fund the adjusted research budget of 2.0 to 2.3 billion euros a year with no revenue at all, it would be only about seven to eight years — and less once selling, general and administrative expenses are added.

A price-to-earnings ratio makes no sense for lack of full-year earnings — the third-quarter profit does not change that, since the first nine months show a loss of 1,168.2 million euros. Price-to-book is the more honest figure here: 20,141.7 million euros of market value divided by 17,711.7 million of equity works out to about 1.1 (as of September 30, 2026) — the market pays barely more than the balance sheet states. For buybacks, BioNTech authorized a program of up to 1.0 billion U.S. dollars through May 6, 2027 and had deployed 463.3 million U.S. dollars of it by September 30, 2026. According to the interim report, such repurchases are “subject to the parameters contained in the applicable repurchase plan”; the report contains no statement by management on how it assesses the value of its own stock.

Opportunities and risks at a glance

Opportunities

• Large balance sheet reserve: about 16.2 billion euros of cash and securities, about 17.7 billion euros of equity, little financial debt (September 30, 2026). On paper, that covers about seven to eight years of the planned research budget even without any revenue (our own calculation, see the valuation section).
• A deep-pocketed partner for the lead candidate: Bristol Myers Squibb paid 1.5 billion U.S. dollars upfront, committed 2.0 billion in non-contingent anniversary payments through 2028, and shares profits and losses equally — so BioNTech generally bears only half of the development costs and losses on pumitamig. The 613.0 million euros for 2026 have been recognized as revenue in the third quarter of 2026.
• A broad late-stage pipeline with one bright spot: seven global registrational trials for pumitamig (September 30, 2026); gotistobart extended median overall survival to 18.5 months versus 10.0 months on chemotherapy in stage 1 of the Phase 3 PRESERVE-003 trial (presented on September 14, 2026, data cut-off July 17, 2026).
• Lower costs on shared programs: for a candidate developed with Roche/Genentech, the partner will generally bear future development costs from January 1, 2027, while BioNTech keeps a stake through royalties.
• Buyback program: a repurchase program of up to 1.0 billion U.S. dollars through May 2027, of which 463.3 million U.S. dollars had been deployed by the end of September 2026.

Risks

• The legacy business keeps shrinking: third-quarter 2026 vaccine revenue down 35 percent to 554.3 million euros, after an 18 percent decline for full-year 2025.
• The profit depends on out-licensing revenue: third-quarter 2026 out-licensing revenue exceeds the entire profit (calculation in the third-quarter chapter). The 613.0 million euros from Bristol Myers Squibb are a portion of the contractually committed payments through 2028, and the same amount was already recognized in the third quarter of 2025. The first nine months of 2026 show a 1,168.2 million euro loss and an operating cash outflow of 540.3 million euros.
• Late-stage setbacks: in October 2026 DYNASTY-Breast02 delivered only a “modest” improvement with limited benefit and interstitial lung disease more often than in prior trials with the same candidate; BNT113 missed its first dual primary endpoint.
• Leadership change at the top: the founding couple is leaving the Management Board, the new chief executive takes office by February 1, 2027 at the latest; Sahin has sold his directly held shares under a trading plan, and whether BioNTech will contribute to the founders' new company is open as of September 30, 2026.
• Legal exposure: up to 450 million euros of European Commission repayment risk from CureVac's 2020 contract, carried as a contingent liability without a provision as of September 30, 2026; since October 2026, also a patent lawsuit by Translate Bio and Sanofi against BioNTech itself.
• De facto control by one large shareholder: 40.3 percent at AT Impf GmbH (December 31, 2025); minority shareholders can practically never form a majority against the large shareholder at the Annual General Meeting.

A human conclusion

We started with the founder bonus — the habit of valuing a company through the people who built it. At BioNTech that bonus can no longer be drawn. From February 2027 at the latest, a pharmaceutical executive runs the house while the founding couple builds something new next door. That Ugur Sahin sold his directly held shares in the fall of 2026 under a trading plan set up in advance proves nothing on its own — the Medine stake of about 15.8 percent remains. It only shows that the founder bonus was never a promise anyone had signed.

What remains is an unusual calculation. On one side, a company that reported a 184.5 million euro profit in the third quarter of 2026, but whose revenue was more than half license money and whose cash pile shrank by 470.4 million euros in the same quarter. On the other, 16.2 billion euros of liquidity, little financial debt against 17.7 billion euros of equity, and a partner who has paid billions for a single drug candidate. Soberly put, BioNTech today is less a growing business than a very large cash pile with an expensive research laboratory attached — and the question is whether the laboratory uses up the cash or multiplies it.

No ratio answers that question. A handful of trial readouts will. Until then, only what is measurable can be tracked: quarterly revenue excluding contractual payments, the cash balance, pumitamig's results in its registrational trials — and the fourth-quarter and full-year 2026 numbers BioNTech has scheduled for March 2, 2027.

What you make of it is your decision. And that is exactly as it should be.

Sources

• BioNTech SE — interim report on Form 6-K for the period ended September 30, 2026, filed November 3, 2026 (SEC EDGAR, CIK 0001776985; revenue by source, impairments, balance sheet, buyback, legal proceedings, InstaDeep)
• BioNTech SE — third-quarter 2026 earnings release, Exhibit 99.1 to the Form 6-K filed November 3, 2026 (guidance, quotes from Zapata and Sahin)
• BioNTech SE and DualityBio — topline results of the Phase 3 DYNASTY-Breast02 trial, Exhibit 99.1 to the Form 6-K filed October 26, 2026
• BioNTech SE — primary analysis of the AHEAD-MERIT trial (BNT113), Exhibit 99.1 to the Form 6-K filed October 13, 2026
• BioNTech SE — proposal of KPMG as auditor from fiscal year 2027, Form 6-K filed September 18, 2026
• Pfizer and BioNTech — FDA approval of the XFG-adapted vaccine, Exhibit 99.1 to the Form 6-K filed August 27, 2026
• Ugur Sahin — first Form 4 covering the sales, filed September 8, 2026, and last Form 4 of October 9, 2026
• BioNTech SE — interim report on Form 6-K for the period ended June 30, 2026, filed August 4, 2026
• BioNTech SE — second-quarter 2026 earnings release, Exhibit 99.1 to the Form 6-K filed August 4, 2026 (guidance cut, buyback program, 14 ongoing pivotal trials)
• BioNTech SE — appointment of Guido Oelkers as Chief Executive Officer, Exhibit 99.1 to the Form 6-K filed August 3, 2026
• BioNTech SE — annual report on Form 20-F for 2025, filed March 10, 2026 (figures for 2023 to 2025, risk factors, major shareholders, notes)
• BioNTech SE — annual report on Form 20-F for 2023, filed March 20, 2024 (source of the 2021 and 2022 figures)
• BioNTech SE — interim report on Form 6-K for the period ended March 31, 2026, filed May 5, 2026
• All SEC filings by BioNTech SE (CIK 0001776985)
• Fundamental data (market value, share count, price-to-book ratio, 52-week range), as of August 12, 2026; the market value calculation in the text instead uses the share count as of September 30, 2026 and the third-quarter 2026 buyback price documented in the interim report (EUR 81.24 or $93.23 per ADS)

Disclaimer: This article is journalistic commentary and expressly not investment advice, not a buy or sell recommendation, and not a solicitation to buy or sell securities. Shares of biotechnology companies without current earnings can be highly volatile; a total loss of the capital employed is possible. All figures come from the primary documents named above and carry the as-of dates stated there; later developments are not reflected. Positions held by the operator are disclosed daily; where one exists, it appears as a notice at the top of this deep dive.